Processa Pharmaceuticals (PCSA) Receivables (2012 - 2018)

Processa Pharmaceuticals' (PCSA) quarterly Receivables came in at $164002.0 in Q2 2018, up 1312.23% on a QoQ basis from $11613.0 in Q3 2015.

Processa Pharmaceuticals (PCSA) Receivables (2012 - 2018) Analysis & Trends

Processa Pharmaceuticals (PCSA) has 5 years of Receivables data on file, last reported at $164002.0 in Q2 2018.

Quarterly Receivables changed N/A year-over-year to $164002.0 in Q2 2018, while the trailing twelve-month figure through Jun 2018 was $164002.0 (changed N/A YoY) and the FY2014 annual result came in at $1310.0, down 93.18% from the prior year.
Receivables rose to $164002.0 in Q2 2018, from $11613.0 in the prior quarter.
In the past five years, Receivables ranged from a high of $164002.0 in Q2 2018 to a low of $1310.0 in Q4 2014.
A 3-year average of $43062.4 and a median of $17702.5 in 2014 frame the typical range for Receivables.
The widest YoY moves for Receivables: up 61.94% in 2014, down 93.18% in 2014.
Tracing PCSA's Receivables over 3 years: stood at $1310.0 in 2014, then surged by 786.49% to $11613.0 in 2015, then soared by 1312.23% to $164002.0 in 2018.
The last three Receivables figures came in at $164002.0 (Q2 2018), $11613.0 (Q3 2015), and $15060.0 (Q2 2015), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	138.04 Bn	130.18 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	85.98 Bn	77.98 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	64.37 Bn	59.19 Bn	1.37 Bn	1.93 Bn
4	Moderna	57.67 Bn	52.53 Bn	52.00 Mn	160.00 Mn
5	BeOne Medicines	41.94 Bn	36.84 Bn	1.53 Bn	1.06 Bn
6	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	912.74 Mn
7	BioNTech SE	27.75 Bn	9.35 Bn	668.28 Mn	1.09 Bn
8	Insmed	27.24 Bn	26.08 Bn	358.27 Mn	215.33 Mn
9	Royalty Pharma	27.03 Bn	26.20 Bn	-	-
10	Processa Pharmaceuticals	6.05 Mn	6.05 Mn	-	-

Download Data